Answers are grounded in this paper and cite their sources.
Background: Breast cancer remains the most common and second lethal cancer in females. HER-2/neu is one of the most important amplified oncogene in breast cancer. The amplification of HER-2 is correlated with decreased survival, metastasis, and early recurrence. The amplification of HER-2/neu gene and synthesis of the protein are reported in 10%-34% of breast cancer cases associated with tumor size, advanced tumor stage, high-grade tumor, young age at diagnosis, absence of steroid hormone receptor, and lymph node involvement.
No takes yet. Share an insight, caveat, or question.
Shandiz et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: